Cannabis and Carbamazepine (Tegretol)
Brand names: Tegretol, Tegretol XR, Carbatrol, Equetro, Epitol
Important Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice. Do not start, stop, or modify your use of Carbamazepine or cannabis without consulting your doctor or pharmacist. If you experience adverse effects, seek immediate medical attention. Individual responses to drug combinations vary significantly.
Overview
Carbamazepine is an anticonvulsant and mood stabilizer used for epilepsy, trigeminal neuralgia, and bipolar disorder. It is one of the most potent inducers of CYP3A4 and other hepatic enzymes, making it a frequent source of significant drug interactions. The interaction between carbamazepine and cannabis, particularly CBD, is classified as high risk because carbamazepine can dramatically reduce CBD blood levels, potentially eliminating its therapeutic effect, while CBD can simultaneously increase carbamazepine levels, risking toxicity. This bidirectional pharmacokinetic interaction creates a clinically dangerous scenario. Patients who add cannabis (particularly CBD products) to carbamazepine therapy may experience increased carbamazepine side effects or toxicity—including dizziness, ataxia, diplopia, and potentially life-threatening hyponatremia or cardiac conduction abnormalities. Conversely, patients who rely on CBD for seizure control may find it ineffective due to carbamazepine's aggressive CYP3A4 induction, which accelerates CBD metabolism. This interaction requires active medical management and is not safely navigated without professional guidance.
How They Interact
Carbamazepine is one of the strongest known inducers of CYP3A4, CYP2B6, CYP2C9, and CYP1A2, as well as UGT enzymes and P-glycoprotein. This induction increases the metabolism of virtually any co-administered substrate of these enzymes. CBD and THC are both primarily metabolized by CYP3A4 and CYP2C9, meaning carbamazepine can dramatically accelerate their clearance—studies from the Epidiolex program showed that carbamazepine co-administration reduced CBD plasma levels by approximately 30-40%. Simultaneously, CBD is a moderate inhibitor of CYP3A4 and CYP2C19, which are involved in carbamazepine metabolism. This inhibition can increase carbamazepine and its active metabolite carbamazepine-10,11-epoxide, potentially pushing levels into the toxic range. The epoxide metabolite is particularly concerning as it is pharmacologically active and its accumulation is associated with neurotoxicity. This bidirectional interaction—induction reducing cannabinoid levels while inhibition increases carbamazepine levels—creates a complex, high-risk pharmacokinetic scenario.
Cannabinoid-Specific Interactions
| Cannabinoid | Interaction with Carbamazepine |
|---|---|
| THC | Carbamazepine's potent CYP3A4 and CYP2C9 induction significantly accelerates THC metabolism, potentially reducing its psychoactive and therapeutic effects. Patients may find that their usual cannabis dose is less effective while on carbamazepine, potentially leading to compensatory dose escalation with associated risks. THC does not significantly inhibit carbamazepine metabolism. |
| CBD | This is the most clinically significant aspect of the interaction. Carbamazepine reduces CBD levels by 30-40% through CYP3A4 induction, potentially rendering CBD therapy subtherapeutic. Simultaneously, CBD inhibits CYP3A4, increasing carbamazepine and carbamazepine-10,11-epoxide levels, risking neurotoxicity. This bidirectional interaction has been documented in the Epidiolex clinical program and requires close monitoring. |
| CBG | CBG (cannabigerol) is also metabolized by CYP enzymes that carbamazepine induces. Patients using full-spectrum cannabis products should be aware that carbamazepine will likely reduce the levels of most cannabinoids, not just THC and CBD. |
Symptoms to Watch For
- ⚠Carbamazepine toxicity symptoms: dizziness, double vision (diplopia), unsteady gait (ataxia), nausea, vomiting
- ⚠Reduced effectiveness of cannabis/CBD therapy
- ⚠Hyponatremia (low sodium) from carbamazepine potentiation
- ⚠Cardiac conduction abnormalities at toxic carbamazepine levels
- ⚠Increased seizure risk if relying on CBD for seizure control that becomes subtherapeutic
Recommendations
- 1This combination requires active medical management—do not start or stop cannabis products while on carbamazepine without consulting your neurologist or psychiatrist.
- 2If CBD is being used for seizure control, carbamazepine co-administration will significantly reduce CBD levels—your neurologist needs to know this to make appropriate dosing decisions.
- 3Monitor for signs of carbamazepine toxicity (dizziness, double vision, unsteady walking, nausea) especially in the first weeks after starting CBD-containing cannabis products.
- 4Request carbamazepine blood level monitoring when starting, stopping, or changing the dose of cannabis products, especially CBD-dominant products.
- 5Consider whether an alternative anticonvulsant with less enzyme-inducing potential (such as levetiracetam or lamotrigine) might be more compatible if cannabis use is important to your treatment plan.
Research Summary
The carbamazepine-CBD interaction has been well characterized through the Epidiolex clinical development program. Population pharmacokinetic analyses showed that carbamazepine co-administration reduced CBD exposure by approximately 30-40%, necessitating higher CBD doses to achieve therapeutic levels. Conversely, CBD increased carbamazepine-10,11-epoxide levels by up to 35% in some patients, leading to toxicity symptoms that required carbamazepine dose reduction. These findings were published in Clinical Pharmacology & Therapeutics in 2019. The carbamazepine-THC interaction has been less formally studied, but the pharmacokinetic basis for reduced THC efficacy through CYP induction is well established. A 2018 case series documented three patients who experienced carbamazepine toxicity after initiating CBD-rich cannabis products, with resolution upon carbamazepine dose adjustment. The FDA's Epidiolex prescribing information explicitly notes the carbamazepine interaction and recommends monitoring.
Frequently Asked Questions
Why is the carbamazepine-cannabis interaction considered high risk?
It is a bidirectional interaction: carbamazepine dramatically reduces cannabis/CBD effectiveness by speeding up its metabolism, while CBD increases carbamazepine levels and its toxic metabolite, risking serious side effects. This creates a dual problem—less benefit from cannabis and more risk from carbamazepine—that requires careful medical management.
Can I still use CBD for seizures if I take Tegretol?
CBD may still provide some benefit, but carbamazepine will reduce CBD levels by 30-40%, meaning you may need higher doses to achieve therapeutic effects. This must be managed by your neurologist, who may need to adjust both medications and monitor drug levels closely. Alternative anticonvulsants with less enzyme-inducing potential may be better suited for combination with CBD.
Should I switch from carbamazepine to another seizure medication if I want to use cannabis?
This is a conversation to have with your neurologist. Anticonvulsants like levetiracetam, lamotrigine (with some caveats), and lacosamide have less CYP enzyme-inducing potential and may be more compatible with cannabis use. However, any medication changes must be made gradually and under medical supervision to prevent seizure recurrence.
How quickly does the interaction take effect?
Carbamazepine's enzyme-inducing effects reach steady state over 2-4 weeks. If you start carbamazepine while already using cannabis, you may notice decreasing cannabis effectiveness over this period. If you add cannabis/CBD to existing carbamazepine therapy, increases in carbamazepine levels can begin within days and progress as CBD accumulates. Blood level monitoring is essential during these transition periods.